Uniphar plc

Half-Year Trading Update and Notice of Results

Dublin, London | 29 July 2025: Uniphar plc (the "Group" or "Uniphar"), an international diversified healthcare services business, today announces the following unaudited trading update for the six months ended 30 June 2025.

The business achieved double-digit adjusted EPS growth in the first half of 2025, ahead of the Group's expectations, driven by a strong trading performance with ca. 8% organic gross profit growth and lower finance costs.

Divisional performance:

·      Uniphar Pharma delivered double-digit organic gross profit growth during the period and remains on track to deliver double-digit organic gross profit growth for the full year.

·      Uniphar Medtech achieved high single-digit organic gross profit growth during the half and expectations of high single-digit organic gross profit growth for the full year remain unchanged.

·      Uniphar Supply Chain & Retail delivered low single-digit organic gross profit growth during the half and remains on track to deliver low single-digit organic gross profit growth for the full year.

The Group continues to maintain a strong liquidity position, with Net Bank Debt/EBITDA of 1.9x at the end of June 2025. The €35m share buyback programme announced with FY 2024 results was completed during the period.

Outlook

Uniphar enters the second half of this year with strong trading momentum. Declining interest rates favourably impacting finance costs will be a tailwind to current year EPS expectations.

M&A continues to play an important role in Uniphar's growth strategy, and the Group maintains a disciplined approach to capital allocation, while managing an active pipeline of acquisition opportunities to further enhance the Group's growth potential.

Ger Rabbette, Uniphar Group Chief Executive Officer said:

"Uniphar has had a strong first half, achieving significant organic gross profit growth. We expect to continue this progress into the second half and meet our growth objectives for each of our three divisions for the full year.  We remain confident of reaching our €200m EBITDA target by 2028, with at least 80% of our growth being organic."

Notice of Results

The Group expects to publish its interim results for the six months ended 30 June 2025 at 07:00 am (BST) on 2 September 2025.   

A conference call for analysts and investors will be held at 9.00 am (BST) on 2 September 2025 to discuss the Group's interim results. Analysts and investors who wish to participate should visit www.uniphar.ie to register. 

The Company's interim results press release and presentation will also be available on the website at 07.00 am (BST) on 2 September 2025 at www.uniphar.ie.

--- ENDS ---

Contact details

About Uniphar plc 

Headquartered in Dublin, Ireland, the Uniphar Group is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain & Retail. The Group is active in Europe, North America, APAC and MENA and delivers to 160+ countries.

The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth, and profitability.

Uniphar Supply Chain & Retail

Uniphar Supply Chain & Retail is the leading pharmaceutical wholesaler in Ireland with a growing symbol group offering of retail pharmacies. The Group's strategy for Uniphar Supply Chain & Retail is to grow our wholesale market share, our symbol group network and our own brand, in-licenced and consumer products portfolio.

Uniphar Medtech

Uniphar Medtech is a leading Pan-European medical device distributor and solutions partner. The Group's strategy for Uniphar Medtech is to grow our service offering across Europe and expand our addressable market by serving new specialities and new manufacturers.

Uniphar Pharma

Uniphar Pharma operates a global business with high value services across the lifecycle of a pharmaceutical product. We enable pharma and biotech companies to bring innovative medicines to global markets and provide healthcare professionals with access to medicines they can't source through traditional channels. Our strategy is to build a leading platform to provide the specialist support and expertise needed to improve access to these medicines.